BioSpace News Archive

Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab.

OptraSCAN®, a leading end-to-end digital pathology solution provider, announced that Karkinos Healthcare has begun using the high-performance OptraSCAN Digital pathology platform to enhance care for their patient population.

Analysis Group, announced that a study it coauthored helped support Blueprint Medicines’ label expansion of AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult patients with advanced systemic mastocytosis (AdvSM), after at least one systemic therapy, in Europe.

PayZen, a mission-driven fintech company delivering healthcare’s Patient Affordability Platform, today announced that they have attained Service Organization Control (SOC) 2 Type II Certification.

Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping multimodal genetic information across cell states and over time.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced its participation in the Kansas City Heart Rhythm Symposium, being held on August 20-21, 2022.

QPharma, the leading provider of cloud-based compliance solutions, today launched the next version of Ti OrderPoint®, a next-generation direct-to-rep (DTR) solution.

The European Investment Bank is providing €22 million in financing to Ryvu Therapeutics, a Polish clinical-stage drug discovery and development company focusing on novel small molecule therapies that address unmet medical needs in oncology.

BioPorto A/S announced interim financial results for the first six months of 2022 and business progress for the second quarter of 2022.

JOYSBIO, one of the world’s leading manufacturers of lateral flow rapid test kits, is proud to announce the development of two Monkeypox tests, both of which deliver results in 15 minutes or less.